A new drug developed by Australian researchers has shown promising results in reducing sepsis in a Phase II clinical trial involving 180 patients. The carbohydrate-based treatment works by calming a ...

Pneumocystis is an unwieldy genus of fungal pathogens that cause severe pneumonia, particularly in immunocompromised people ...

PrEP is one of the most powerful tools in HIV prevention. Yet for many Black LGBTQ+ people, getting access to the medication is far harder than it should be.

One Application Seeks European Commission Authorization; Other Application Would Facilitate Availability in Low- and Lower-Middle-Income Countries - - Both Applications Will Be Assessed in Parallel ...

Discover how UCSF is leading the charge in Long COVID research, uncovering key findings that advance our understanding of the ...

In the early months of the COVID-19 pandemic, UC San Francisco researchers were already seeing signs of lingering symptoms in ...

Fungal infections are becoming deadlier as drug resistance spreads and treatment options stall. Researchers at McMaster University discovered that a molecule called butyrolactol A can dramatically ...

Opinion: "While the obstacles we face may be significant, Lenacapavir represents a monumental breakthrough in the fight ...

The U.S. Food and Drug Administration approved the use of Yeztugo as an HIV prevention or “PrEP” medication in June 2025 as ...

An AIDS drug already shown to help prevent spread of the virus in gay men also works for heterosexual men and women, two studies in Africa found.

A trial was about to launch for a vaccine that would ward off the HIV virus. It would be an incredible breakthrough. Then it ...

Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...